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ABSTRACT: In this work, we report a novel surface plasmon resonance (SPR)
based live-cell biosensing platform to measure and compare the binding aﬃnity of
vascular endothelial growth factor (VEGF) to vascular endothelial growth factor
receptor (VEGFR) and VEGF to bevacizumab. Results have shown that bevacizumab
binds VEGF with a higher association rate and aﬃnity compared to VEGFR. Further,
this platform has been employed to mimic the in vivo condition of the VEGF−
VEGFR angiogenic switch. Competitive binding to VEGF between VEGFR and
bevacizumab was monitored in real-time using this platform. Results demonstrated a
signiﬁcant blockage of VEGF−VEGFR binding by bevacizumab. From the results, it is
evident that the proposed strategy is simple and highly sensitive for the direct and
real-time measurements of bevacizumab drug eﬃcacy to the VEGF−VEGFR
angiogenic switch in living SKOV-3 cells.
In the past decade, cancer has been reported as the secondmajor cause of death in the United States.1 Although there
are several types of cancer, a common cause for any type of
cancer is the abnormal growth of cells.2−4 Further, very often,
cancer cells form a tumor. A tumor larger than a millimeter will
starve itself for oxygen and energy, unless new blood vessels are
built to provide supplies. During such circumstances, a process
known as angiogenesis is found to be involved in building new
blood vessels for many types of cancer.5 Angiogenesis is a
complex process and is deﬁned as the growth of new blood
vessels from existing vessels.6,7 Mediators of angiogenesis such
as vascular endothelial growth factor (VEGF) stimulate
endothelial cells to secrete proteases and plasminogen
activators. Cells will then migrate, proliferate, and eventually
diﬀerentiate to form a new lumen vessel.8 Several pathological
conditions involve or mimic the angiogenic process. Cancer
switches on angiogenesis by breaking the balance between
productions of angiogenic stimulus and inhibiting factors.9,10
Vascular endothelial growth factor receptor (VEGFR) refers to
a family of endothelial cell membrane receptors that bind with
the VEGFs secreted by tumors. VEGF−VEGFR binding
process is the key point of neovascularization.11,12 Targeting
the endothelial cells receptor binding and activation process is a
promising strategy for cancer repression. However, there are
several questions about the VEGF−VEGFR angiogenic switch
including the binding kinetics remain unclear.
Despite the fact that there are several unanswered
fundamental questions, biochemical therapies targeting angio-
genic switches are rapidly emerging in the anticancer
pharmaceutical industry. Further, the side eﬀects associated
with biochemical therapies are negligible upon comparison with
chemotherapy and radiotherapy.13 At present, FDA approved
about 100 antibodies based cancer therapy for regulating the
VEGF−VEGFR angiogenic switch.14−16 One such approved
antibody is bevacizumab, a humanized anti-VEGF monoclonal
antibody generated by engineering the VEGF binding residues
of a murine neutralizing antibody into the framework of the
consensus human immunoglobulin G1 (IgG1).17 Bevacizumab
recognizes, binds and blocks all biologically active forms of
VEGF that interact with VEGFRs.18 The binding epitope of
VEGF for bevacizumab has been determined structurally in a
previous study: Fab domain of bevacizumab binding centers on
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Gly-88 residue of the human VEGF.19 The eﬃcacy of
bevacizumab against various cancer types has been demon-
strated in several clinical studies.20−24 (Supporting Information,
Table S1)
Although there are several clinical studies and trials on the
drug eﬃcacy of bevacizumab on cancers, only a few
fundamental studies have been reported on the interaction
between bevacizumab and VEGF.25,26 A kinetics study on
VEGF-bevacizumab binding is essential to elucidate the
fundamental mechanism of bevacizumab inhibition to the
VEGF−VEGFR angiogenic switch. Traditional biological
techniques employed to measure the binding kinetics of
VEGF and bevacizumab include Western Blot and
ELISA.27,28 These techniques measure biomolecular binding
only at a single time point and therefore are not useful for real-
time monitoring. Electrochemical biosensors provide continu-
ous monitoring of biomolecular bindings. However, a labeling
procedure is required in order to detect non redox-active
analytes.29,30 The recent rapid development of surface plasmon
resonance (SPR) biosensors has oﬀered an engineering
solution to overcome these limitations. SPR oﬀers highly
sensitive label-free detection, and it is also a powerful tool for
binding kinetic studies.31−33 SPR transforms the refractive
index change induced by biomolecular binding events on the
sensing surface into the shift of the plasmon extinction
wavelength. Real-time biomolecular binding kinetics and
aﬃnity information can be obtained by tracking this shift
versus time. Earlier, work by Yu et al. has shown an in vitro real-
time monitoring of VEGF-bevacizumab binding using SPR.34
However, the experimental conditions were not comparable to
the in vivo VEGF−VEGFR angiogenic switch as it was
performed with a commercial VEGF solution. Therefore, an
alternative real-time binding kinetic study method is urgently
needed to mimic the in vivo VEGF−VEGFR angiogenic switch
for fundamental studies and drug development. In our previous
study, we have successfully demonstrated real-time monitoring
of VEGF expression from living human ovarian carcinoma cells
using SPR.35 By integrating a mini cell culture system into the
SPR ﬂow system, we were able to maintain live-cell culture on
the ceiling of the SPR ﬂow chamber to realize VEGF
measurements from live-cells. In this study, we have measured
and compared the binding aﬃnity of VEGF to VEGFR and
VEGF to bevacizumab. Finally, we employed this live-cell
sensing platform to mimic the in vivo condition of the VEGF−
VEGFR angiogenic switch. The results demonstrated a
signiﬁcant blockage of VEGF−VEGFR binding by bevacizu-
mab. With this successful prove of concept, we believe that this
simple and highly sensitive biomimic platform possesses great
potential in the future biomolecular binding studies and drug
evaluation.
■ EXPERIMENTAL SECTION
Reagents. 11-Mercaptoundecanoic acid (MUA) was
purchased from Asemblon (Redmond, WA). Calcium
ionophore (A23187) and Kreb’s buﬀer were from Sigma-
Aldrich (St. Louis, MO). 1-Ethyl-3-(3-dimethylaminopro-pyl)
carbodiimidehydrochloride (EDC) and N-hydroxysuccinamide
(NHS) were obtained from Alfa Aesar (Ward Hill, MA).
Bevacizumab was kindly donated by Genentech (San Francisco,
CA). Recombinant human VEGF and VEGFR were purchased
from R&D Systems (Minneapolis, MN).
Cell Culture and Viability Test. In order to maintain cell
viability during the measurements, a customized polydimethyl-
siloxane (PDMS) SPR ﬂow chamber gasket was treated by
applying several drops of 0.1% w/v gelatin solution made with
boiling distilled water to cover the entire surface and dried for
12 h. A cell culture Petri dish and an uncoated PDMS gasket
were also prepared and employed as positive and negative
control substrates, respectively. SKOV-3 cells were cultured in
McCoy’s 5A medium added with 1% penicillin and 10% fetal
bovine serum and kept in a 37 °C cell incubator maintained
with a humidiﬁed atmosphere of 5% CO2 and 95% air. A total
of 200 000 cells were seeded on each substrate and kept with
cell culture media for 48 h before experiments. Cell viability on
each substrate was evaluated using a previously reported
ﬂuorescent imaging method35 (described in the Supporting
Information).
Functionalization of the SPR Sensing Surface.
Carboxylic groups were immobilized on the gold SPR chip
(Biosensing Instrument, AZ) by incubation in 1 mM MUA/
ethanol solution for 12 h at 4 °C. The SPR chip was then
washed with copious ethanol and mounted on the SPR
instrument (described in the Supporting Information). After
starting the ﬂowing buﬀer, a solution of 75 mM EDC and 15
mM NHS in water was injected into the ﬂowing buﬀer to
activate the carboxylic groups. Following this, 50 μg/mL of
protein G solution was injected to cover the activated SPR chip
to ensure proper antibody orientation. All injections in this
study were performed with a 20 μL/min rate unless otherwise
speciﬁed.
Living Cell Integration to the SPR System. The ﬂowing
PBS buﬀer was stopped immediately after the SPR chip
functionalization and the immobilization of ligands. The PDMS
gasket in the SPR ﬂow chamber used for surface immobilization
(no cells) was changed to the PDMS gasket with cells, and SPR
ﬂowing buﬀer was changed from PBS (pH = 7.4) to Kreb’s
buﬀer (pH = 7.4) in order to maintain the cell viability during
experiments. The PDMS ﬂow chamber gasket with SKOV-3
cell culture was removed from cell culture media and
thoroughly rinsed with Kreb’s buﬀer to remove cell culture
media and unattached cells before mounting on the SPR ﬂow
chamber for measurements. As shown in Scheme 1, living cells
Scheme 1. Schematic Illustration of the Biomimic System for
Bevacizumab Drug Regulation Study
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are attached on the ceiling of a customized SPR ﬂow cell
chamber; VEGFR is immobilized on the SPR chip. A chemical
stimulation is used to induce the rapid secretion of VEGF from
cells. Bevacizumab is added to the system to actively block the
VEGF−VEGFR angiogenic switch. Competitive binding to
VEGF between VEGFR and bevacizumab was monitored in
real-time.
■ RESULTS AND DISCUSSION
Cell Viability in the SPR Flow Chamber. As shown in
Figure 1, the cell count within the same area on the tissue
culture plate, the gelatin coated gasket, and the uncoated gasket
are found to be 166 ± 8 (n = 3), 227 ± 10 (n = 3), and 79 ± 7
(n = 3), respectively. With a signiﬁcant enhancement of cell
attachment compared to uncoated gaskets, gelatin coated
gaskets were demonstrated to be a suitable substrate to
maintain the cell viability for live-cell experiments in the SPR
ﬂow chamber.36
Optimization of Bevacizumab Dosing. In order to
determine the optimal dose of bevacizumab for this study, we
have investigated the SPR response corresponding to various
amounts of bevacizumab immobilized on the gold sensing
surface. Initially, a known concentration of bevacizumab (5 μg/
mL, 10 μg/mL, 30 μg/mL, 50 μg/mL, 70 μg/mL) was injected
to the functionalized SPR chip. A solution of 3 μg/mL VEGF
(recombinant, Sigma-Aldrich) was then injected to pass
through the sensing surface. The SPR measurement was
repeated three times for every single bevacizumab concen-
tration. Figure 2 shows the results corresponding to one set of
measurements. The resulting SPR response for each
bevacizumab concentration was plotted against time (70 μg/
mL data not shown). It is evident that the amount of VEGF
bound to the 50 μg/mL bevacizumab sensing surface did not
show a signiﬁcant diﬀerence than the amount of VEGF bound
to the 30 μg/mL bevacizumab sensing surface (Figure 2). This
observation can be attributed to the following two possible
reasons: (i) 30 μg/mL is the saturation concentration of
bevacizumab on the surface or (ii) 3 μg/mL VEGF injection
can be completely captured by 30 μg/mL surface bound
bevacizumab. Our previous study indicated that even if SKOV-
3 cells reached 100% conﬂuency in the SPR ﬂow chamber, the
VEGF release did not reach 3 μg/mL.35 Therefore, the dynamic
range of the sensor employed in this work is suitable for the
live-cell measurements. We employed 30 μg/mL of bevacizu-
mab as the optimum concentration for further binding studies.
Speciﬁcity Study of VEGF-Bevacizumab Binding.
Bevacizumab is a humanized anti-VEGF monoclonal antibody
generated by engineering the VEGF binding residues of a
murine neutralizing antibody into the framework of the human
IgG.37 Any nonspeciﬁc binding to other biomolecules is
expected to aﬀect the eﬃcacy of this drug. Earlier, we have
demonstrated the aﬃnity and reproducibility of VEGF-
bevacizumab binding. In this experiment, we further inves-
tigated the speciﬁcity of the VEGF-bevacizumab interaction.
VEGF−VEGFR binding and activation is the most important
step of the angiogenesis process, which is also the target of
most angiogenesis regulation therapy strategies, including
bevacizumab.38,39 Thus, it is crucial to investigate the
interaction between bevacizumab and VEGFR. Similarly, a
bevacizumab layer was formed on the activated SPR gold
surface by injecting 10 μg/mL of bevacizumab. Following this,
3 μg/mL VEGF and VEGFR were injected and passed the two
bevacizumab covered gold chips, respectively. As shown in
Figure 3A, a 25.1 mDeg baseline shift was observed in the SPR
sensogram upon comparing the stable baseline positions before
and after the injection. Such a baseline shift can be attributed to
the VEGF-bevacizumab binding. However, no signiﬁcant
baseline shift was detected for the VEGFR−bevacizumab
interaction (Figure 3B). From the results, it is evident that
bevacizumab competitively binds with VEGF and thereby
minimizes the amount of VEGF available to the VEGF−
VEGFR interaction.
Figure 1. Merged ﬂuorescent images (Hoechst channel &
MitoTracker Red channel) of SKOV-3 cells on diﬀerent type of
substrates: Petri dishes (exposure time 400 ms), gelatin coated gaskets
(exposure time 200 ms), and uncoated gaskets (exposure time 200
ms).
Figure 2. (A) SPR response corresponding to 3 μg/mL VEGF for
each surface bound bevacizumab concentration: 5 μg/mL (red), 10
μg/mL (blue), 30 μg/mL (purple), 50 μg/mL (green); (B) SPR
baseline shift induced by each diﬀerent surface concentration of
bevacizumab (n = 3): 8.5 ± 1.3 (5 μg/mL), 26.1 ± 3.6 (10 μg/mL),
96.1 ± 9.8 (30 μg/mL), 107.2 ± 9.3 (50 μg/mL), 111.6 ± 11.2 (70
μg/mL).
Analytical Chemistry Article
dx.doi.org/10.1021/ac402659j | Anal. Chem. 2014, 86, 7305−73107307
Binding Kinetics Study of VEGF−VEGFR and VEGF−
Bevacizumab Interactions. To demonstrate the drug eﬃcacy
of bevacizumab, binding kinetics of VEGF−VEGFR and
VEGF−bevacizumab interactions was measured and compared.
After the surface activation and modiﬁcation of the SPR gold
chip, 30 μg/mL of bevacizumab was immobilized on top of the
protein G layer. Another SPR chip was immobilized by direct
injection of 30 μg/mL of VEGFR onto the activated surface
without the protein G layer. A solution of 2 μg/mL VEGF was
injected to the ﬂow chamber after surface functionalization.
The SPR sensorgram corresponding to the responses on VEGF
binding to bevacizumab (blue) and VEGFR (red) is shown in
Figure 4A. A modiﬁed pseudo-ﬁrst-order kinetics equation40
was used to determine the association rate constants (described
in Supporting Information):
=R
t
d
d
ka[VEGF]Rmax
where R is the SPR signal at time t, ka is the association rate
constant which indicates the binding aﬃnity between two
molecules, [VEGF] is the concentration of VEGF, and Rmax is
the maximum response of the immobilized ligand (bevacizu-
mab or VEGFR). The value of (dR/dt) for each sample was
determined by calculating the maximum slope of the
association curve using Matlab 7.1 (SP3). The weight
concentration of VEGF was converted to molar concentration
(47.6 nM). The maximum SPR response of the surface bound
bevacizumab is 1321 mDeg and the ka for bevacizumab is 1.45
± 0.05 × 105 M−1 s−1 (n = 3) (repeated trails, 1.63 ± 0.06 ×
105 M−1 s−1; 1.41 ± 0.05 × 105 M−1 s−1). Similarly, the
maximum SPR response of the surface bound VEGFR is 1078
mDeg, the ka for VEGFR is 0.83 ± 0.03 × 105 M−1 s−1 (n = 3)
(repeated trails, 0.91 ± 0.04 × 105 M−1 s−1; 0.82 ± 0.03 × 105
M−1 s−1). We also obtained the binding aﬃnity information for
both interactions from Figure 4A by measuring the SPR
baseline shift upon VEGF binding. VEGF−bevacizumab
binding induced a 92.7 ± 4 mDeg baseline shift (repeated
trails, 106.5 ± 6 mDeg; 89.8 ± 3 mDeg), whereas VEGF−
VEGFR binding induced a 60.2 ± 3 mDeg baseline shift
(repeated trails, 69.3 ± 3 mDeg; 57.4 ± 2 mDeg). Results of ka
and SPR baseline shift from three similar experiments with
diﬀerent batch of SKOV-3 cells are shown in parts B and C of
Figure 4, respectively. Each experiment was repeated three
times with intertrail coeﬃcient of variation (CV) ranging from
0.034 to 0.056. These results indicate that bevacizumab binds
VEGF with a higher rate and aﬃnity compared to VEGFR.
Biomimic Drug Regulation Study on VEGF−VEGFR
Interaction. The biomimic system was employed to evaluate
the bevacizumab drug regulation on the VEGF angiogenic
switch. VEGFR was immobilized on the SPR gold sensing
surface by the aforementioned method. The PDMS gasket with
living cells was then integrated to the SPR system. After
restarting the experiment, 500 μm Ca2+ ionophore (A23187)
Figure 3. (A) SPR sensorgram of surface bound bevacizumab
interacting with VEGF. Inset: enlarged sensorgram of the response
upon VEGF binding. (B) SPR sensorgram of surface bound
bevacizumab interacting with VEGFR. Inset: enlarged sensorgram of
the response upon VEGFR binding.
Figure 4. (A) SPR sensorgram of VEGF binding response to bevacizumab (blue line) and VEGFR (red line). (B) Association rate constants (ka) of
VEGF−bevacizumab binding (blue) and VEGF−VEGFR binding (red) calculated for each trial of experiment. (n = 3). (C) Binding aﬃnity indicated
by SPR baseline shift of VEGF−bevacizumab binding (blue) and VEGF−VEGFR binding (red) for each trial (n = 3).
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was injected to induce rapid exocytosis of VEGF from the
SKOV-3 cells.29 In Figure 5A, the red line represents the SPR
response of VEGF exocytosis binding to VEGFR on the sensing
surface (control experiment). The peak between ∼50 s and
∼250 s is attributed to the refractive index change induced by
the Ca2+ ionophore (A23187) passing through the sensing
surface. Following the plateau, the baseline is stabilized at 103.7
± 8 mDeg (repeated trails, 105.6 ± 9 mDeg, 113.2 ± 10
mDeg). This SPR baseline shift indicates that VEGF released
from SKOV-3 cells has bound to the VEGFR. The blue line
depicts the SPR response of VEGF exocytosis binding to
surface VEGFR under the regulation of bevacizumab (drug
regulation experiment). A solution of 30 μg/mL bevacizumab
was added to the ﬂowing buﬀer to bind the VEGF secretion in
this group. This data, upon comparison with the control
experiment, has shown that the SPR baseline dropped by 82.5
± 9.6 mDeg after the Ca2+ ionophore (A23187) stimulation.
Similar results were observed in experiments with diﬀerent
batch of SKOV-3 cells. We anticipate this sudden drop of
baseline as a result of the surface refractive index decrease
caused by the rapid binding event occurred between VEGF and
bevacizumab in the ﬂowing buﬀer. However, further experi-
ments are essential to validate this assumption. Following the
plateau, the baseline slowly increased toward the original
position to −25.8 ± 2 mDeg (repeated trails, −18.4 ± 2 mDeg;
−10.5 ± 2 mDeg) as a consequence of the VEGF exocytosis
being carried away from the sensing surface. No signiﬁcant
baseline increase was observed after the induced exocytosis,
thereby conﬁrming that the VEGF−VEGFR pathway was
successfully blocked by bevacizumab in the ﬂow chamber.
Figure 5B shows the SPR baseline shift with and without
bevacizumab regulation obtained from three similar experi-
ments with diﬀerent batch of SKOV-3 cells. Each experiment
was repeated three times with intertrail CV ranging from 0.081
to 0.18. These results indicate that the amount of VEGF bound
to VEGFR was signiﬁcantly decreased under the regulation of
bevacizumab.41
■ CONCLUSION
In summary, we have constructed a biomimic system for the
VEGF−VEGFR angiogenic switch in SPR and investigated its
potential application on antineoplastic drugs development. To
the best of our knowledge, this is the ﬁrst report showing direct
and real-time measurements of drug eﬀect to the VEGF−
VEGFR angiogenic switch on live-carcinoma cells. SKOV-3
cells and the bevacizumab antibody were used as the cell model
and the drug model to evaluate the strategy. SPR exhibited
excellent sensitivity and linear dynamic range toward VEGF
and bevacizumab interactions. VEGF−bevacizumab binding
indicated a higher association rate constant and binding aﬃnity
than VEGF−VEGFR binding. The bevacizumab drug regu-
lation study reveals successful blockage of VEGF−VEGFR
binding and activation process. We have outlined a highly
sensitive and simple strategy for the direct and real-time
measurements of bevacizumab drug eﬃcacy to the VEGF−
VEGFR angiogenic switch on living SKOV-3 cells. A similar
strategy can be adopted to develop and evaluate other types of
medicine in the future.
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